<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="144566">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01843985</url>
  </required_header>
  <id_info>
    <org_study_id>YLDZH-OS-1</org_study_id>
    <nct_id>NCT01843985</nct_id>
  </id_info>
  <brief_title>Observational Study of Survival Outcomes of Stage IV Cancer Patients</brief_title>
  <official_title>Observational Study of Survival Times of Stage IV Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cure Cancer Worldwide Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cure Cancer Worldwide Corporation</source>
  <oversight_info>
    <authority>China: Institutional Review Board, Yang Ling Demonstration Zone Hospital</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients diagnosed with Stage IV cancer (solid tumors only) are evaluated to determine
      whether they are candidates for traditional chemotherapy.  If eligible, patients are offered
      traditional chemotherapy, low-dose chemotherapy, or palliative care.  If ineligible,
      patients are offered low-dose chemotherapy or palliative care.  Patients will be monitored
      for 5 years and survival data recorded.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>N/A</study_design>
  <primary_outcome>
    <measure>survival</measure>
    <time_frame>months 1, 2, 3, 4, 6, 9, 12, 18, 24, 36, 48, 60</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Stage IV Cancer (Solid Tumors Only)</condition>
  <condition>Survival</condition>
  <arm_group>
    <arm_group_label>1. Eligible RCT/Elect RCT</arm_group_label>
    <description>Eligible for regular chemotherapy, elects and receives regular chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2. Eligible RCT/Elect LDC</arm_group_label>
    <description>Eligible for regular chemotherapy, elects and receives low-dose chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3. Eligible RCT/Elect PCO</arm_group_label>
    <description>Eligible for regular chemotherapy, elects and receives palliative care only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4. Ineligible RCT/Elect LDC</arm_group_label>
    <description>Ineligible for regular chemotherapy, elects and receives low-dose chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5. Ineligible RCT/Elect PCO</arm_group_label>
    <description>Ineligible for regular chemotherapy, elects and receives palliative care only</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        primary care clinic
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Presenting with Stage IV cancer (solid tumors only)

        Exclusion Criteria:

          -  Patient declines inclusion
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>gary smith</last_name>
    <phone>5207492035</phone>
    <email>garylsmith2@msn.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yang Ling Demonstration Zone Hospital</name>
      <address>
        <city>Yang Ling</city>
        <state>Shaanxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 27, 2013</lastchanged_date>
  <firstreceived_date>April 27, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stage IV cancer</keyword>
  <keyword>Survival</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
